Results 211 to 220 of about 164,310 (312)

Complex Cerebral Artery Anomaly Rete-like Formation of the Terminal Carotid and Middle Cerebral Arteries with Bilateral A1 Segments Fenestrations. [PDF]

Diagnostics (Basel)
Nestorovic D, Nikolic I, Savic A, Radanovic D, Miletic M, Cvetic V.   +5 more
europepmc   +1 more source

Initial experiences of the Optima™ coil system in intracranial aneurysm treatment: surgical and interventional approach to safety and efficacy in terms of cerebral arteries. [PDF]

Acta Cir Bras
Ulusoy BSS, Altay ÇM, Onay M, Binboga AB, Kaya M.   +4 more
europepmc   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

Accuracy of an nnUNet Neural Network for the Automatic Segmentation of Intracranial Aneurysms, Their Parent Vessels, and Major Cerebral Arteries from MRI-TOF. [PDF]

AJNR Am J Neuroradiol
Colombo E, de Boer M, Bartels L, Regli L, van Doormaal T.   +4 more
europepmc   +1 more source

ANEURYSMS OF THE MIDDLE CEREBRAL ARTERY

Annals of Surgery, 1953
E, CAMPBELL, C W, BURKLUND
openaire   +3 more sources

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

Feasibility of U-Net model for cerebral arteries segmentation with low-dose computed tomography angiographic images with pre-processing methods. [PDF]

Sci Rep
Kang SH, Kim K, Shim J, Lee Y.
europepmc   +1 more source

Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment

ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi, Maria Giulia Bellicini, Marianna Adamo, Andrea Pilotto, Marco Metra, Alessandro Padovani, Riccardo Proietti   +6 more
wiley   +1 more source

Histological Analysis of Intracranial Cerebral Arteries for Elastin Thickness, Wall Thickness, and Vessel Diameters: An Atlas for Computational Modeling and a Proposed Predictive Multivariable Model of Elastin Thickness. [PDF]

J Clin Med
Thiyagarajah N, Witek A, Davison M, Butler R, Erdemir A, Tsiang J, Hussain MS, Prayson R, Bain M, Moore NZ.   +9 more
europepmc   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source